Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Next Previous
Trial Profile

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evinacumab (Primary) ; Evinacumab (Primary)
  • Indications Dyslipidaemias; Hypertriglyceridaemia
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 27 Jun 2019 Results from two phase I studies of evinacumab (SAD and MAD studies) published in the Circulation
  • 29 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
  • 16 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top